Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (297)	1/8/2003 5:16:32 PM
From: tuck	Read Replies (2) \| Respond to of 897

Double dang! >>Wednesday January 8, 4:15 pm ET NEW YORK--(BUSINESS WIRE)--Jan. 8, 2003--Antigenics Inc. (NASDAQ: AGEN - News) announced today that it plans to publicly offer approximately 4,500,000 shares of its common stock. The offering would be made from a registration statement covering $100 million in securities that became effective in August 2002. UBS Warburg LLC is acting as the lead underwriter in this offering and Needham & Company, Inc., Morgan Keegan & Company, Inc. and Ryan Beck & Co., Inc. are acting as co-managers. Antigenics would grant to the underwriters an option to purchase an additional 675,000 shares of its common stock within 30 days after the offering to cover over-allotments incurred in the offering.<< snip Cheers, Tuck